Deciphera Pharmaceuticals (DCPH) 10-K2021 FY Annual report

Filed: 8 Feb 22, 5:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: adagrasib, adulterated, afatinib, Africa, AmMax, AP, autophagic, Bio, bioresearch, Brazil, Brazilian, carryforward, catabolic, CDPA, CI, cloud, Colorado, combat, commandeered, conflicting, counterfeit, CPA, CPDA, CRAF, cultivate, cut, cyberattack, cybersecurity, DEI, dismissed, EGFR, eleven, encephalopathy, Endeavor, engineered, Erasca, erlotinib, escape, fibrosarcoma, fluorescence, fluorescent, flux, fuse, fusion, gathering, Gefitinib, GFP, GMP, gouging, governor, gradual, green, height, hemorrhage, hutchmed, hybrid, inconsistent, instructed, intangible, intentionally, interdependent, internationally, interoperable, IRS, KGaA, leaked, lysosome, maker, mCherry, MEKi, MOTION, NCCN, nilotinib, node, nonstatutory, osimertinib, override, paradigm, persistence, ph, PhRMA, Plenary, posture, PRC, proof, rationale, recency, redemption, reexamining, regression, reimposition, roadmap, routine, RTK, runway, Russia, Russian, safest, seller, shareholder, shifted, sincerely, sinking, SmPC, sotorasib, Sprint, stably, steadily, stolen, surge, synergy, systematic, tampered, theft, translation, trust, unaffected, unapproved, uncertainly, undetected, unexpectedly, unfit, unfounded, unnecessary, unremitted, unrestricted, unutilized, upstream, vaccination, vaginal, Virginia, vision, voice, withholding, worsening, Zug

Removed: amending, antibody, anticancer, anticipation, assay, asthenia, ASU, back, biochemical, block, blood, branch, breast, censored, centrally, circulating, confirmed, deduction, depicted, displacing, dosed, dot, dry, emergence, epinephrine, escalate, execution, expressed, FASB, filer, finalized, fined, flat, float, glioblastoma, golden, Google, grown, headache, heterogeneity, illustrated, image, insensitive, intolerant, Japan, judged, kinome, launching, legend, marginal, measurable, mesothelioma, micromolar, millimolar, mM, multiforme, muscular, necessitated, neuropathy, Notably, parachute, peripheral, plasma, predictor, prematurely, programmed, pronounced, red, refractory, registrational, reposition, retained, retrospective, reversed, Roche, rotation, screen, specificity, stabilization, syndrome, systemic, tangible, TCJA, tissue, top, TTP, unaudited, unconfirmed, underwent, unnecessarily, unresponsive, vascular, vote, Wall, weakly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated DCPH transcripts

DCPH similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Deciphera Pharmaceuticals, Inc. (the “Company”) for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Thomas P. Kelly, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: February 8, 2022	By:	/s/ Thomas P. Kelly
		Thomas P. Kelly Chief Financial Officer (Principal Financial and Accounting Officer)